Search

Your search keyword '"O. Hars"' showing total 67 results

Search Constraints

Start Over You searched for: Author "O. Hars" Remove constraint Author: "O. Hars"
67 results on '"O. Hars"'

Search Results

2. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial

4. Quantitative ultrasonometry during pregnancy and lactation: a longitudinal study

7. Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole

8. Pregnancy-associated transient osteoporosis of the hip: results of a case-control study

9. Serum Osteocalcin and CTX-MMP Concentration in Young Exercising Thoroughbred Racehorses

10. Speed of sound measurements of the third metacarpal bone in young exercising thoroughbred racehorses

11. Age-Associated Changes in Bone Ultrasonometry of the os calcis

12. Influence of pregnancy and breast-feeding on quantitative ultrasonometry of bone in postmenopausal women

13. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer

14. Quantitative Ultrasonometrie (QUS) am Os calcaneus bei Frauen. Erstellung eines deutschen Referenzkollektives

16. The influence of hormone replacement therapy (HRT) on serum leptin concentration in postmenopausal women

17. Quantitative Ultrasound of Os Calcis in Postmenopausal Women with Spine and Hip Fractures

18. Knochendichte bei Patientinnen mit Mammakarzinom im Vergleich zu gesunden matched-pair Kontrollen

19. Stiffness index identifies patients with osteoporotic fractures better than ultrasound velocity or attenuation alone

22. Quantitative Ultraschallsonographie (QUS) am Os calcaneus bei postmenopausalen Frauen

23. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study

24. The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonometry in pre and postmenopausal women

25. Influence of pregnancy and breast-feeding on quantitative ultrasonometry of bone in postmenopausal women

26. The influence of menopause and body mass index on serum leptin concentrations

27. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women

28. Age changes of calcaneal ultrasonometry in healthy German women

30. Blue light excited retinal intercepts cellular signaling

35. In Early Breast Cancer, the Ratios of Neutrophils, Platelets and Monocytes to Lymphocytes Significantly Correlate with the Presence of Subsets of Circulating Tumor Cells but Not with Disseminated Tumor Cells.

36. Clinical experience with misoprostol vaginal insert for induction of labor: a prospective clinical observational study.

37. Prevention of breast cancer treatment-induced bone loss in premenopausal women treated with zoledronic acid: Final 5-year results from the randomized, double-blind, placebo-controlled ProBONE II trial.

38. Subsequent fracture risk of women with pregnancy and lactation-associated osteoporosis after a median of 6 years of follow-up.

39. Pregnancy-associated transient osteoporosis of the hip: results of a case-control study.

40. Pregnancy-associated osteoporosis: a case-control study.

41. Comparison of combined low-dose hormone therapy vs. tibolone in the prevention of bone loss.

42. Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era.

43. Comparison of dual-energy X-ray absorptiometry with six quantitative ultrasonometry devices in women with hip fractures.

44. Quantitative ultrasonometry during pregnancy and lactation: a longitudinal study.

45. Effect of anastrozole on hormone levels in postmenopausal women with early breast cancer.

46. Persistency with estrogen replacement therapy among hysterectomized women after the Women's Health Initiative study.

47. Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer.

48. Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer.

49. Impact of BMI on serum estradiol and bone turnover markers in postmenopausal women with hormone-sensitive early breast cancer treated with anastrozole.

50. Influence of a patient information program on adherence and persistence with an aromatase inhibitor in breast cancer treatment--the COMPAS study.

Catalog

Books, media, physical & digital resources